Evidence map›Paper›PMID 42728438›Full record

ArticleWorld journal of urology2026

Six-factor-based stratification system for enfortumab vedotin monotherapy in pre-treated patients with metastatic or locally advanced urothelial carcinoma.

Yuto Matsushita, Satoru Taguchi, Taku Naiki, Gaku Ishikawa, Yu Nakamura, Jimpei Miyakawa, Takashi Nagai, Tomoyuki Kaneko, Hiroki Kubota, Hayato Hoshina and 47 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

57 authors.

Yuto Matsushita *Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
Satoru TaguchiDepartment of Urology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. satorutaguchi33@gmail.com.
Taku Naiki *Department of Nephro-urology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.
Gaku IshikawaDepartment of Urology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
Yu NakamuraDepartment of Urology, Kyorin University School of Medicine, Tokyo, Japan.
Jimpei MiyakawaDepartment of Urology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Takashi NagaiDepartment of Nephro-urology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.
Tomoyuki KanekoDepartment of Urology, Teikyo University School of Medicine, Tokyo, Japan.
Hiroki KubotaDepartment of Urology, Kainan Hospital, Yatomi, Japan.
Hayato HoshinaDepartment of Urology, Jichi Medical University, Tochigi, Japan.
Jun KameiDepartment of Urology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Aya NiimiDepartment of Urology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Yuta YamadaDepartment of Urology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Daisuke ObinataDepartment of Urology, Nihon University School of Medicine, Tokyo, Japan.
Shigenori KakutaniDepartment of Urology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Masashi ShiozakiDepartment of Urology, Shinshu University School of Medicine, Nagano, Japan.
Kento OzawaDepartment of Urology, Seirei Mikatahara General Hospital, Hamamatsu, Japan.
Michio NodaDepartment of Urology, The Fraternity Memorial Hospital, Tokyo, Japan.
Daichi HirataDepartment of Urology, Tokyo Metropolitan Tama Medical Center, Fuchu, Japan.
Yuichi KitagawaDepartment of Urology, Iwata City Hospital, Iwata, Japan.
Yukihiro YoshimiDepartment of Urology, Chutoen General Medical Center, Kakegawa, Japan.
Nozomi SugiyamaDepartment of Urology, Musashino Red Cross Hospital, Tokyo, Japan.
Nobuhiko ShimizuDepartment of Nephro-urology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.
Yohei TsubouchiDepartment of Urology, Konan Kosei Hospital, Konan, Japan.
Keigo SatoDepartment of Urology, National Center for Global Health and Medicine, Tokyo, Japan.
Kosuke UchidaDepartment of Urology, Hamamatsu Medical Center, Hamamatsu, Japan.
Shinya WatanabeDepartment of Urology, Fujieda Municipal General Hospital, Fujieda, Japan.
Jun TakahashiDepartment of Urology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Toshiharu MorikawaDepartment of Nephro-urology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.
Yoichi MoriDepartment of Urology, Ome Municipal General Hospital, Ome, Japan.
Takashi MurataDepartment of Urology, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan.
Taro MurataDepartment of Urology, Tokyo Teishin Hospital, Tokyo, Japan.
Taketo KawaiDepartment of Urology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Takehiro TanakaDepartment of Pharmacy, The University of Tokyo Hospital, Tokyo, Japan.
Yukari UemuraBiostatistics Section, Department of Data Science, Center of Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.
Tappei TakadaDepartment of Pharmacy, The University of Tokyo Hospital, Tokyo, Japan.
Sayuri TakahashiDepartment of Urology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Toshiki ItoDepartment of Urology, Fujieda Municipal General Hospital, Fujieda, Japan.
Masao NagataDepartment of Urology, Hamamatsu Medical Center, Hamamatsu, Japan.
Hideyo MiyazakiDepartment of Urology, National Center for Global Health and Medicine, Tokyo, Japan.
Satoshi KurokawaDepartment of Urology, Anjo Kosei Hospital, Anjo, Japan.
Yukio YamadaDepartment of Urology, Musashino Red Cross Hospital, Tokyo, Japan.
Ryo SatoDepartment of Urology, Chutoen General Medical Center, Kakegawa, Japan.
Atsushi OtsukaDepartment of Urology, Iwata City Hospital, Iwata, Japan.
Yusuke SatoDepartment of Urology, Tokyo Metropolitan Tama Medical Center, Fuchu, Japan.
Hiroaki NishimatsuDepartment of Urology, The Fraternity Memorial Hospital, Tokyo, Japan.
Yukihiro UmemotoDepartment of Urology, Nagoya City University West Medical Center, Nagoya, Japan.
Hiroshi FuruseDepartment of Urology, Seirei Mikatahara General Hospital, Hamamatsu, Japan.
Yoshiyuki AkiyamaDepartment of Urology, Shinshu University School of Medicine, Nagano, Japan.
Yutaka EnomotoDivision of Urology, Mitsui Memorial Hospital, Tokyo, Japan.
Satoru TakahashiDepartment of Urology, Nihon University School of Medicine, Tokyo, Japan.
Tetsuya FujimuraDepartment of Urology, Jichi Medical University, Tochigi, Japan.
Tohru NakagawaDepartment of Urology, Teikyo University School of Medicine, Tokyo, Japan.
Hiroshi FukuharaDepartment of Urology, Kyorin University School of Medicine, Tokyo, Japan.
Takahiro YasuiDepartment of Nephro-urology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.
Haruki KumeDepartment of Urology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Teruo InamotoDepartment of Urology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study aimed to identify prognostic factors and develop a prognostic stratification system for progression-free survival (PFS) and overall survival (OS) in patients with locally advanced or metastatic urothelial carcinoma (la/m UC) treated with enfortumab vedotin (EV).

methodsWe retrospectively analyzed 387 patients with la/m UC who received EV monotherapy and evaluated the prognostic factors using the Cox proportional hazards regression model. We then used the significant factors to derive a system for predicting prognosis.

resultsThe median PFS and OS were 7.6 and 14.6 months, respectively. Multivariable analysis revealed six significant factors common to both PFS and OS: poor Eastern Cooperative Oncology Group performance status (≥ 1), presence of aberrant histology (histological subtypes or divergent differentiation), presence of bone metastasis, anemia (hemoglobin < 10 g/dL), high C-reactive protein levels (> 0.5 mg/dL), and hypercalcemia (corrected calcium > 10.2 mg/dL). Based on the number of positive factors, patients were categorized into three groups: 147 patients with none or one factor (low-risk group), 92 patients with two factors (intermediate-risk group), and 148 patients with three or more factors (high-risk group). The log-rank test indicated significant differences in both PFS and OS among the three groups, with C-indices of 0.634 and 0.700 for PFS and OS, respectively.

conclusionsSix factors were identified as common prognostic factors for both PFS and OS in la/m UC patients receiving EV monotherapy. The newly developed prognostic risk stratification system based on these factors is clinically useful, particularly for predicting OS.

Indexed as

Antibodies, MonoclonalCarcinoma, Transitional CellUrinary Bladder NeoplasmsAgedAged, 80 and overFemaleHumansMaleMiddle AgedNeoplasm StagingPrognosisProgression-Free SurvivalRetrospective StudiesRisk AssessmentSurvival RateAntibodies, Monoclonalenfortumab vedotinEnfortumab vedotinPrognostic systemRisk stratificationUrothelial carcinoma

Identifiers

PMID42728438
PMCPMC13569552

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.